PriskA Pilot Study

A Pilot Study to Test the PCOS Risk Algorithm (PriskA)

Background of the study:

With a prevalence up to 15%, polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Women with PCOS present with diverse features, including reproductive features such as irregular menstrual cycles, subfertility, hirsutism and pregnancy complications, metabolic features such as obesity, insulin resistance, metabolic syndrome, pre-diabetes, type 2 diabetes and cardiovascular factors, and psychological features such as anxiety and depression. Because of the reproductive, metabolic and cardiovascular risk factors it is important to screen and inform these women. However, up to 70% of the affected women remain undiagnosed. In academic hospitals (tertiary care) the diagnosis PCOS will rarely be missed by gynecologists. However, in peripheral hospitals or for internal medicine physicians, PCOS and its criteria are less well known.

Therefore, the PCOS risk algorithm (PriskA), a digital tool to use in the assessment of PCOS in patients with signs and symptoms of PCOS, is developed. To exclude patients with a WHO I status, the tool exclude women with low Luteinizing Hormone (LH) and low Follicle-Stimulating Hormone (FSH) in advance. Women with LH and FSH within the normal range will be used in the algorithm for further assessment. The algorithm uses clinical data including age, BMI and information about irregular menstrual cycle in combination with anti-Mullerian hormone (AMH), testosterone and Sex Hormone Binding Globulin (SHBG) to generate a risk score ranging from 0-1. Women having a risk score below 0.2 are considered having a low risk of having PCOS, women with a risk score 0.2-0.8 are considered having a moderate risk of having PCOS and women with a risk score above 0.8 have a high risk of having PCOS.

Objective of the study:

In this study we aim to assess the validity of the PriskA algorithm to diagnose PCOS in a pilot study with patients presenting with signs and symptoms of PCOS. The study also aims to collect information on the user experience from the clinicians and to provide useful information to support the design of a validation study.

Study design:

This study will be a prospective, mono-center observational pilot study and it will be conducted at the Department of Reproductive Endocrinology at the Erasmus University Medical Center Rotterdam, the Netherlands. We estimate that the study will be completed within one year.

Study population:

Women with symptoms of PCOS who are referred to the Department of Reproductive Endocrinology at the Erasmus University Medical Center Rotterdam, and are undergoing a standardized screening (COLA screening, which stands for: (menstrual) Cycle problems, Oligomenorrhea and Amenorrhea). The COLA screening is part of standard clinical care. Women with one or more symptoms of PCOS will be included in the study. Women who eventually getting the diagnosis PCOS by standard screening will be labelled as cases and women who have one PCOS symptom and did not get the diagnosis PCOS will be labelled as controls.

Primary study parameters/outcome of the study:

The validity of the PriskA tool to diagnose PCOS, by assessing the sensitivity and specificity of the risk probabilities of 0.2 and 0.8.Parameters that will be used:

• Testosterone level in serum (using Elecsys using Cobas 6000)
• SHBG level in serum (using Elecsys using Cobas 6000).
• AMH level in serum (using Elecsys using Cobas 6000).
• LH level in serum (using Elecsys using Cobas 6000)
• FSH level in serum (using Elecsys using Cobas 6000)
• Cycle information
• Age
• BMI

Secondary study parameters/outcome of the study:

A secondary study parameter is to assess the number (percentage) and characteristics of patients with a PriskA score between 0.2-0.8. Characteristics will include: menstrual cycle information, age, BMI, serum LH, serum FSH, serum AMH, serum testosterone, serum SHBG, serum progesterone, serum estradiol, total follicle count, PCOS phenotype (if applicable), WHO diagnosis or other endocrinological diagnosis.

Another secondary parameter is the user experience of the PriskA tool. This will be collected from every user by a questionnaire. Questionnaires will be collected from every used when he/she completed 20 patients during the study.

Study Overview

• Status: Completed
• Conditions: Polycystic Ovary Syndrome
• Intervention / Treatment: Other: PriskA tool

• Study Type: Observational
• Enrollment (Actual): 150

Contacts and Locations

• Study Contact: Name: Kim van der Ham, MSc; Phone Number: +31648492656; Email: k.vanderham@erasmusmc.nl
• Study Contact Backup: Name: Yvonne V Louwers, Dr.; Email: y.louwers@erasmusmc.nl

Study Locations

• Netherlands
  • Rotterdam, Netherlands
    • Erasmus University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 45 years (Child, Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Women with symptoms of PCOS who are referred to the Department of Reproductive Endocrinology at the Erasmus University Medical Center Rotterdam, and are undergoing a standardized screening (COLA screening, which stands for: (menstrual) Cycle problems, Oligomenorrhea and Amenorrhea) will be asked to participate. The COLA screening is part of standard clinical care. Women with one or more symptoms of PCOS will be included in the study. Women who eventually getting the diagnosis PCOS by standard screening will be labelled as cases and women who have one PCOS symptom and did not get the diagnosis PCOS will be labelled as non-PCOS.

Description

Inclusion Criteria:

• Women with signs and symptoms of PCOS, including: irregular or absent menstrual cycle, hirsutism or polycystic ovarian morphology who undergoing a standardized screening (COLA screening)
• Age range 16-45 years
• Sufficient command of the Dutch language
• Signed written informed consent

Exclusion Criteria:

• Documented ongoing pregnancy
• Malignancy (documented malignancy, documentation of current radiation therapy or chemotherapy in medical record)
• If transvaginal ultrasound is not possible or it is inappropriate
• Not willing to share clinical data with Roche and Evidencio
• Use of hormonal medication in the past three months, including hormonal IUD

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Cases; Women with PCOS according to the Rotterdam criteria.	Other: PriskA tool; PriskA tool is an algorithm that generates a risk score of having PCOS.
Controls; Women with PCOS.	Other: PriskA tool; PriskA tool is an algorithm that generates a risk score of having PCOS.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sensitivity and specificity of the risk probabilities (<0.2 and >0.8) of the PriskA tool	The PriskA tool generates a risk score ranging from 0-1. Women having a risk score below 0.2 are considered having a low risk of having PCOS, women with a risk score 0.2-0.8 are considered having a moderate risk of having PCOS and women with a risk score above 0.8 have a high risk of having PCOS.	Through study completion, an average of 1 year.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patiens with a PriskA score between 0.2 and 0.8.	A secondary study parameter is to assess the number (percentage) of patients with a PriskA score between 0.2-0.8.	Through study completion, an average of 1 year.
Diagnosis of patients with a PriskA score between 0.2 and 0.8.	The official diagnosis of patients with a PriskA score between 0.2 and 0.8, including WHO I or III, or other endocrinological diagnosis.	Through study completion, an average of 1 year.
PCOS phenotype of patients with a PriskA score between 0.2 and 0.8 and PCOS diagnosis.	A secondary study parameter is to investigate the phenotype of women who receive the diagnosis PCOS but have PriskA score between 0.2 and 0.8. This will be stratified in phenotype A, B, C or D.	Through study completion, an average of 1 year.
User experience of PriskA tool	Another secondary parameter is the user experience of the PriskA tool. This will be collected from every user by a questionnaire. Questionnaires will be collected from every user when he/she completed 20 patients during the study.	Through study completion, an average of 1 year.

Collaborators and Investigators

• Sponsor: Erasmus Medical Center
• Collaborators: Roche Diagnostics

Study record dates

Study Major Dates

• Study Start (Actual): March 1, 2023
• Primary Completion (Actual): September 1, 2023
• Study Completion (Actual): December 4, 2023

Study Registration Dates

• First Submitted: March 1, 2023
• First Submitted That Met QC Criteria: March 14, 2023
• First Posted (Actual): March 27, 2023

Study Record Updates

• Last Update Posted (Actual): February 28, 2024
• Last Update Submitted That Met QC Criteria: February 26, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Endocrine System Diseases; Ovarian Cysts; Cysts; Ovarian Diseases; Adnexal Diseases; Gonadal Disorders; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Polycystic Ovary Syndrome
• Other Study ID Numbers: NL82155.078.22

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No